The American Association for Cancer Research (AACR) today released its ninth annual Cancer Progress Report, which details cancer trends in the U.S. and reports research progress in cultivating new therapies.
The report states that between August 2018 and July 2019, 27 cancer treatments were approved by the U.S. Food and Drug Administration (FDA)—the highest number in the history of the AACR report. Notably, these treatments included the first molecularly targeted therapeutic approved for treating cancers with a specific genetic biomarker regardless of cancer type, and the first immunotherapeutic for use in the treatment of breast cancer.
The report also noted several significant demographic shifts in the cancer patient population:
The report argues that the continuing prevalence of cancer in the U.S. and its social implications underscore the need for adequate funding for cancer research and the development of new approaches to prevention, early detection, and treatment. It specifically calls on elected leaders to:
For more information about the findings of AACR’s 2019 Cancer Progress Report, and to access the entire text of the report, visit the report’s home page.